Skip to main content

Table 5 Analysis of survival outcomes in different subgroups of the IMRT group versus the IMRT/chemo-therapy group

From: Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma

Factor

OS

P

DFS

P

LRRFS

P

DMFS

P

Age

 ≤ 45 years

86.7% vs. 96.0%

0.282

80.0% vs. 92.0%

0.238

93.3% vs. 96.0%

0.696

86.7% vs. 96.0%

0.299

 > 45 years

93.6% vs. 86.5%

0.257

89.4% vs. 86.5%

0.620

97.9% vs. 94.6%

0.415

93.6% vs. 94.6%

0.369

Sex

 Male

90.9% vs. 90.9%.

0.980

84.1% vs. 88.6%

0.581

95.5% vs. 93.2%

0.643

90.9% vs. 95.5%

0.708

 Female

94.4% vs. 88.9%

0.553

94.4% vs. 88.9%

0.553

100% vs .100%

1.000

94.4% vs. 94.4%

0.504

T category

 T1

100% vs. 94.4%

0.378

100% vs. 94.4%

0.378

100% vs. 94.4%

0.378

100% vs. 100%

1.000

 T2

92.7% vs. 94.1%

0.825

87.8% vs. 91.2%

0.639

97.6% vs. 94.1%

0.452

90.2% vs. 94.1%

0.571

 T3

71.4% vs 70.0%

0.907

51.1% vs. 70.0%

0.791

100% vs. 100%

1.000

71.4% vs. 90.0%

0.362

N category

 N0

90.5% vs. 84.2%

0.539

85.7% vs. 84.2%

0.817

95.2% vs. 100%

0.342

95.2% vs. 94.7%

0.215

 N1

92.7% vs. 93.0%

0.964

87.8% vs. 90.7%

0.678

97.6% vs. 93.0%

0.331

90.2% vs. 95.3%

0.389

TNM stage

 II

94.5% vs. 94.2%

0.935

90.9% vs.92.3%

0.802

98.2% vs.94.2%

0.283

92.7% vs. 96.2%

0.462

 III (T3N0M0)

71.4% vs. 70.0%

0.907

57.1% vs.70.0%

0.801

85.7% vs.100%

0.232

85.7% vs. 90.0%

0.648

  1. OS Overall survival, DFS Disease-free survival, LRRFS Locoregional relapse–free survival, DMFS Distant metastasis–free survival